Progestogen-only Injectables

Filter Standards and Guidance documents

FSRH Clinical Guideline: Progestogen-only Injectable (December 2014, Amended October 2020)

24 October 2020

This guidance provides evidence-based recommendations and good practice points for health professionals on the use of progestogen-only injectables (depot medroxyprogesterone acetate (DMPA), Depo-Provera) currently available in the UK. It is intended for any health care professional or health service providing contraception or conception advice in the UK.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH CEU Statement: Self-Administration of Sayana Press® (September 2015)

01 September 2015

The CEU supports the self administration of Sayana Press® because of its potential benefits to women and services. It offers women greater choice and more autonomy over their contraception and fertility.

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH New Product Review: Sayana Press® (June 2013)

01 June 2013

Injectable progestogen-only contraception is a popular and effective method of contraception and until now, in the UK has largely been administered as Depo-Provera®, an intramuscular (IM) injection of 150mg medroxyprogesterone acetate (DMPA).

You are welcome to download our freely available Guideline documents by clicking on the document title above.

This document is up-to-date

FSRH Guideline-related CPD Q&A: Progestogen-only Injectable Contraception (December 2014)

16 May 2016

1 CPD credit can be claimed for reading the guidance and 1 CPD credit can be claimed for answering the questions.

This resource is available to members/candidates of FSRH.

This document is up-to-date